NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders,
Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders,
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies First Quarter 2021 Financial Results Conference Call. As a reminder, today s conference call is being recorded.
I d now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.
Juan Sanchez
Vice President of Corporate Communications and Investor Relations
Good morning and thank you all for joining us for today s conference call. Our earnings press release provides a corporate update and details of the company s financial results for the first quarter ended March 31, 2021. This press release crossed the wire a short time ago and is available on our website at intracellulartherapies.com.